Research Article
The informatics core of the Alzheimer’s Disease Neuroimaging Initiative

Arthur W. Toga and Karen L. Crawford

Alzheimer`s & Dementia, 2010, 6(3), 247-256. DOI: 10.1016/j.jalz.2010.03.001

Abstract

The Alzheimer’s Diseases Neuroimaging Initiative project has brought together geographically distributed investigators, each collecting data on the progression of Alzheimer’s disease. The quantity and diversity of the imaging, clinical, cognitive, biochemical, and genetic data acquired and generated throughout the study necessitated sophisticated informatics systems to organize, manage, and disseminate data and results. We describe, here, a successful and comprehensive system that provides powerful mechanisms for processing, integrating, and disseminating these data not only to support the research needs of the investigators who make up the Alzheimer’s Diseases Neuroimaging Initiative cores, but also to provide widespread data access to the greater scientific community for the study of Alzheimer’s Disease.

ASCI-ID: 285-24

View Fulltext

Similar Articles


Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004

Clinical core of the Alzheimer’s disease neuroimaging initiative: Progress and plans

Alzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006

The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plans

Alzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007

Alzheimer’s Disease Neuroimaging Initiative in Europe

Alzheimer`s & Dementia, 2010, 6(3), 280-285. DOI: 10.1016/j.jalz.2010.03.005

The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board

Alzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010

Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and future

Alzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413

Drug treatment of Alzheimer’s disease patients leads to expression changes in peripheral blood cells

Alzheimer`s & Dementia, 2010, 6(5), 386-393. DOI: 10.1016/j.jalz.2009.12.004

White matter is altered with parental family history of Alzheimer’s disease

Alzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003

Influence of apolipoprotein E ε4 on rates of cognitive and functional decline in mild cognitive impairment

Alzheimer`s & Dementia, 2010, 6(5), 412-419. DOI: 10.1016/j.jalz.2009.12.003

Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004

Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects

Alzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008

Clinical core of the Alzheimer’s disease neuroimaging initiative: Progress and plans

Alzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006

The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes

Alzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002

Temporal lobe functional activity and connectivity in young adult APOE ε4 carriers

Alzheimer`s & Dementia, 2010, 6(4), 303-311. DOI: 10.1016/j.jalz.2009.07.003

The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plans

Alzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007

Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans

Alzheimer`s & Dementia, 2010, 6(3), 265-273. DOI: 10.1016/j.jalz.2010.03.013

Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology Core

Alzheimer`s & Dementia, 2010, 6(3), 274-279. DOI: 10.1016/j.jalz.2010.03.012

Alzheimer’s Disease Neuroimaging Initiative in Europe

Alzheimer`s & Dementia, 2010, 6(3), 280-285. DOI: 10.1016/j.jalz.2010.03.005

The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board

Alzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010

Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009

Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and future

Alzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011

An examination of Alzheimer’s disease case definitions using Medicare claims and survey data

Alzheimer`s & Dementia, 2010, 6(4), 334-341. DOI: 10.1016/j.jalz.2009.09.001

Deliberative assessment of surrogate consent in dementia research

Alzheimer`s & Dementia, 2010, 6(4), 342-350. DOI: 10.1016/j.jalz.2009.06.001

Priorities for research consortia on Alzheimer's disease

Alzheimer`s & Dementia, 2010, 6(4), 359-362. DOI: 10.1016/j.jalz.2010.05.2017

Improving Alzheimer‘s disease phase II clinical trials

Alzheimer`s & Dementia, 2013, 9(1), 39-49. DOI: 10.1016/j.jalz.2012.02.002